COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bupropion and Cigarette-Related Cues in Smokers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03920319
Recruitment Status : Completed
First Posted : April 18, 2019
Last Update Posted : April 18, 2019
Information provided by (Responsible Party):
University of California, Los Angeles

Brief Summary:
Randomized, double-blind, before-after controlled trial to assess changes in regional brain activation in response to cigarette-related cues from before to after treatment with bupropion (vs placebo).

Condition or disease Intervention/treatment Phase
Smoking Smoking, Tobacco Drug: Bupropion Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind, before-after controlled trial
Masking: Double (Participant, Care Provider)
Masking Description: Matching placebo pills
Primary Purpose: Basic Science
Official Title: Effect of Bupropion Treatment on Brain Activation Induced by Cigarette-Related Cues in Smokers
Actual Study Start Date : January 1, 2004
Actual Primary Completion Date : December 31, 2005
Actual Study Completion Date : December 31, 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Bupropion
Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
Drug: Bupropion
Bupropion 150 mg sustained release
Other Names:
  • bupropion HCl
  • Wellbutrin

Placebo Comparator: Placebo
Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
Other: Placebo

Primary Outcome Measures :
  1. Craving ratings [ Time Frame: 8 weeks ]
    Participants were instructed to respond from 1 (definitely not) to 5 (definitely) on the question, "I crave a cigarette right now", after viewing video cues.

Secondary Outcome Measures :
  1. Exhaled carbon monoxide (CO) [ Time Frame: 8 weeks ]
    Participants were asked to hold their breath for as long as possible, ideally 15 seconds, then to breathe out slowly into the mouthpiece of a CO monitor, aiming to empty the lungs completely.

  2. Cigarettes per day [ Time Frame: 8 weeks ]
    Self-reported number of cigarettes smoked daily during the past 7 days [??]

  3. Fagerström Test for Nicotine Dependence (FTND) [ Time Frame: 8 weeks ]
    The FTND contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Treatment-seeking cigarette smoker
  • Meet DSM-IV criteria for nicotine dependence
  • Negative result on urine test for drug use during screening

Exclusion Criteria:

  • History of any Axis I psychiatric diagnosis other than nicotine dependence
  • Medical conditions that might affect brain function
  • Current use of medications that could alter brain function
  • Pregnancy
  • Current illicit drug use other than occasional use of marijuana
Layout table for additonal information
Responsible Party: University of California, Los Angeles Identifier: NCT03920319    
Other Study ID Numbers: Brody011
First Posted: April 18, 2019    Key Record Dates
Last Update Posted: April 18, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors